Ferdinando D'Amico1,2, Fernando Magro3, Laurent Peyrin-Biroulet4, Silvio Danese2. 1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy. 2. Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy. 3. Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal. 4. Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Abstract
BACKGROUND AND AIMS: Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with UC. METHODS: The Pubmed, Embase and Scopus databases were searched up to June 25, 2021 in order to identify studies reporting efficacy and safety data of filgotinib in patients with UC. RESULTS: Data from a phase III study enrolling UC patients with moderate to severe disease show that filgotinib is effective with a reassuring safety profile. Filgotinib treatment is not associated with a greater risk of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, animal studies reported impaired spermatogenesis and histopathological effects on male reproductive organs, making it necessary to deepen this aspect in dedicated human studies. CONCLUSIONS: Filgotinib is an effective and safe drug for treatment of both biologic-naive and biologic-experienced patients with moderate to severe UC and may soon be available.
BACKGROUND AND AIMS: Filgotinib is a small molecule that selectively inhibits Janus kinase [JAK] type 1. It is already approved for the treatment of rheumatoid arthritis and is being evaluated for the management of patients with moderate to severe ulcerative colitis [UC]. The purpose of this review is to provide an overview of the currently available data on filgotinib and to define how to position this new drug in the treatment algorithm of patients with UC. METHODS: The Pubmed, Embase and Scopus databases were searched up to June 25, 2021 in order to identify studies reporting efficacy and safety data of filgotinib in patients with UC. RESULTS: Data from a phase III study enrolling UC patients with moderate to severe disease show that filgotinib is effective with a reassuring safety profile. Filgotinib treatment is not associated with a greater risk of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, animal studies reported impaired spermatogenesis and histopathological effects on male reproductive organs, making it necessary to deepen this aspect in dedicated human studies. CONCLUSIONS: Filgotinib is an effective and safe drug for treatment of both biologic-naive and biologic-experienced patients with moderate to severe UC and may soon be available.
Authors: William J Sandborn; Chinyu Su; Bruce E Sands; Geert R D'Haens; Séverine Vermeire; Stefan Schreiber; Silvio Danese; Brian G Feagan; Walter Reinisch; Wojciech Niezychowski; Gary Friedman; Nervin Lawendy; Dahong Yu; Deborah Woodworth; Arnab Mukherjee; Haiying Zhang; Paul Healey; Julian Panés Journal: N Engl J Med Date: 2017-05-04 Impact factor: 91.245
Authors: R Westhovens; P C Taylor; R Alten; D Pavlova; F Enríquez-Sosa; M Mazur; M Greenwald; A Van der Aa; F Vanhoutte; C Tasset; P Harrison Journal: Ann Rheum Dis Date: 2016-12-19 Impact factor: 19.103
Authors: Kacey Anderson; Yan Xin; Hao Zheng; Chohee Yun; Ellen Kwan; Ann Qin; Florence Namour; Brian P Kearney; Anita Mathias Journal: Clin Pharmacol Drug Dev Date: 2019-12-02
Authors: Rebecca Begley; Kacey Anderson; Timothy R Watkins; Winnie Weng; Lorraine Ampaw; Ann Qin; Brian P Kearney; Anita Mathias Journal: Clin Pharmacol Drug Dev Date: 2020-09-28
Authors: Kevin L Winthrop; Edward V Loftus; Daniel C Baumgart; Walter Reinisch; Chudy I Nduaka; Nervin Lawendy; Gary Chan; Rajiv Mundayat; Gary S Friedman; Leonardo Salese; Andrew J Thorpe; Chinyu Su Journal: J Crohns Colitis Date: 2021-06-22 Impact factor: 9.071